PainReform Announces Receipt of Nasdaq Minimum Bid Price Notification
GlobeNewswire
TEL AVIV, Israel, May 31, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("*PainReform*" or the "*Company*"), a..
TEL AVIV, Israel, May 31, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("*PainReform*" or the "*Company*"), a..
*Allschwil, Switzerland – May 31, 2024*Idorsia Ltd (SIX: IDIA) today announced that data from the Phase 3 study of aprocitentan,..
Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated..